EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study

• Published in: Clinical lung cancer 2021-05, Vol.22 (3), p.e395-e404
• Main Authors: Chang, Qing, Xu, Jianlin, Qiang, Huiping, Teng, Jiajun, Qian, Jialin, Lv, Minfang, Zhang, Yanwei, Lou, Yuqing, Zhao, Yizhuo, Zhong, Runbo, Han, Baohui, Chu, Tianqing
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Cisplatin - administration & dosage; Disease Progression; Drug Administration Schedule; EGFR-TKI therapy; ErbB Receptors - genetics; Female; Gradual disease progression; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Middle Aged; Mutation; Mutation-negative EGFR-T790M; NSCLC; Pemetrexed - administration & dosage; Progression-Free Survival; Prospective Studies; Survival Rate
• ISSN: 1525-7304; 1938-0690
• DOI: 10.1016/j.cllc.2020.06.005

Continuing tyrosine kinase inhibitor (TKI) therapy may be beneficial when patients with non–small-cell lung cancer and EGFR mutations experience gradual disease progression after initial EGFR-TKI treatment. We aimed to compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential treatment after patients’ disease gradually progressed after first-line EGFR-TKI treatment. Patients with gradual progression who were EGFR-T790M mutation negative were randomly divided into two groups. In the concurrent group, patients were treated with pemetrexed plus cisplatin along with the same EGFR-TKI. In the sequential group, patients continued with EGFR-TKI until the disease progressed again, according to RECIST, then switched to chemotherapy. We evaluated the patients’ progression-free survival (PFS) and overall survival times. Ninety-nine patients were enrolled: 49 in the concurrent group and 50 in the sequential group. The median PFS (mPFS) was 7.7 months (95% confidence interval [CI], 3.6-11.7) in the concurrent group and 5.7 months (95% CI, 3.5-7.9) in the sequential group (hazard ratio = 0.66; 95% CI, 0.44-1.00; P = .026), respectively. For the sequential group, the mPFS1 and mPFS2 were 1.8 months (95% CI, 1.4-2.3) and 3.8 months (95% CI, 3.1-4.5), respectively. The median overall survival of the concurrent group was longer than that of the sequential group (20.0 vs. 14.7 months; hazard ratio = 0.52; 95% CI, 0.32-0.85; P = .038). For patients with advanced non–small-cell lung cancer and gradual progression who are EGFR-T790M mutation negative after initial EGFR-TKI therapy, EGFR-TKI combined with chemotherapy confers longer PFS and overall survival than sequential EGFR-TKI and chemotherapy does. This study aimed to compare the efficacy and safety of simultaneous EGFR tyrosine kinase inhibitor (TKI) and chemotherapy with that of sequential treatment after disease gradually progressed from first-line EGFR-TKI treatment and EGFR-T790M mutation negativity. Overall survival, progression-free survival, overall response rate, disease control rate, and adverse events were assessed. EGFR-TKI combined with chemotherapy conferred more survival benefits than sequential EGFR-TKI and chemotherapy.